Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma-Reference-Cited by-同舟云学术

Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma

Published:2005 Issue:8 Volume:104 Page:1620-1626
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Hong David,Lunagomez Simon,Kim E. Edmund,Lee Jeffery H.,Bresalier Robert S.,Swisher Stephen G.,Wu Tsung-Tse,Morris Jeffery,Liao Zhongxing,Komaki Ritsuko,Ajani Jaffer A.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference19 articles.

1. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer

2. Utility of Positron Emission Tomography for the Staging of Patients With Potentially Operable Esophageal Carcinoma

3. Whole-Body FDG Positron Emission Tomographic Imaging for Staging Esophageal Cancer

4. Evaluation of Esophageal Cancer by Positron Emission Tomography

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of [18F]FDG PET/CT on treatment response and progression-free survival of gastroesophageal cancer patients undergoing perioperative FLOT chemotherapy;European Journal of Radiology;2023-06

2. Predictive value of clinical and 18F-FDG-PET/CT derived imaging parameters in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma;Scientific Reports;2022-05-03

3. Predicting the risk of interval distant metastases in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy;Journal of the Formosan Medical Association;2022-02

4. Effect of aspirin on PET parameters in primary non-small cell lung cancer and its relationship with prognosis;BMC Cancer;2020-06-03

Baseline FDG Uptake And Peripheral Lymphocyte-Monocyte Ratio For Predicting Chemoradiotherapy Response In Patients With Esophageal Squamous Cell Carcinoma

;Cancer Management and Research;2019-10